Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse
Pain can be classified into three main categories. Nociceptive pain involves the activation of nociceptors – neurons specialized in transmitting information regarding pain that signal to the central nervous system (CNS). Inflammatory pain results from tissue damage and activity of immune cells and the third category is pain caused by damage and/or dysfunction of the nervous system.
Pain therapeutics market is forecast to grow from US$19.7 Billion in 2016 to US$28.8 Billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The US market alone is forecast to be worth US$13.5 Billion in 2023, accounting for 45.2% of the overall pain therapeutics market. Generic products are the main source of market revenue, accounting for over 50% of total market revenue in 2016. This is due mainly to the widespread usage (particularly in the US) of generic opioids, which are far more expensive than other generic analgesics.
There are 817 products in the pain therapeutics pipeline, including 75 for migraine, 118 for inflammatory pain and 255 for neuropathic pain. Some 63% of the pipeline is in the early drug development stages. The most promising drugs within the pipeline include those drugs belonging to the new class of migraine medication, the CGRPR antagonists that have been shown to be an effective preventative therapy for migraines. This class of drugs is forecast to generate an aggregate of US$5 Billion revenue by 2023.
A total of 363 licensing deals for pain therapeutics were completed between 2006 and April 2017, with an aggregate disclosed value of US$11.8 Billion. This highlights pharmaceutical company’s interest in investment in analgesics. These deals varied considerably in terms of value, ranging from US$20,000 to US$1.5 Billion. Over 40 deals were valued at less than US$10m, while 19 were valued above US$200m.
The report “Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse” provides an introduction to the pain market, including disease epidemiology, symptoms, diagnosis, pathophysiology and co-morbidities and complications.
In depth, this report provides the following analysis - - Provides an overview of the landscape for pain marketed products, including product profiles of key marketed products and revenue projections for each of these drugs. - Analyses the pain pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: migraine, inflammatory pain and neuropathic pain. - Detailed analysis of forecast projections to 2023 on a global level, with forecasts also provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Revenue forecasts for the major product categories are also provided. - Assesses the company landscape in pain, with an analysis of the key players, the types of company involved in this disease cluster, and whether this disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenue.
Companies mentioned in this report: Pfizer, Depomed, Pacira, Horizon, Daiichi Sankyo, Novartis, Eli Lilly.
- The pain therapeutics market is forecast to reach $28.8 billion in 2023. What are the key market segments driving this growth? - The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late stage products? - Despite historical high levels of generic drug development, there is a very high proportion of novel drugs in the pipeline. How do failure rates, clinical trial size and clinical trial duration differ by indication and molecular target? - Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market? - What licensing and co-development deals have occurred within this therapy area since 2006?
Reasons to buy
- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the pain therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include neuropathic pain, inflammatory pain (including osteoarthritis pain) and migraine. - Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action. - Analyse the pain therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at pain therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market. - Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value. - Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products. - Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from pain therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market. - Assess the licensing and co-development deal landscape for pain therapies.
Our reports have been used by over 10K customers, including:
KEY FINDINGS The global market for viral vector vaccines is expected to grow at a CAGR of 18.19% over the forecast period of 2019-2027. Promising results from several clinical studies performed by various organizations have emphasized the potential of viral-vector-based vaccines and therapies for gene therapies. MARKET...
Report Scope: This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRP?. The report analyzes the market trends, key medical needs and provides insights into recent...
The global drug of abuse testing market is projected to cross US$ 5 Billion by 2024. Drugs of abuse testing involves detection of one or more illegal and/or prescribed substances in the urine, blood, saliva, hair, or sweat. The use of illicit drugs is increasing across the globe. According to the United Nations Office on Drugs and Crime, nearly...
96 pages •
By Infiniti Research Limited
• Oct 2018
About Polio Polio is a highly contagious disease caused by a human enterovirus of the Picornaviridae family, resulting in paralysis or death. Two types of polio vaccination are available, OPV and IPV. The incidence of polio has been decreasing owing to initiatives by governments globally to drive immunization against...
111 pages •
By Infiniti Research Limited
• Oct 2018
About Sjogren’s Syndrome Sjogren’s syndrome is an autoimmune disorder and the major symptoms of this disorder are dry eyes and dry mouth. The mucous membranes produce reduced tears, and moisture-secreting glands in the mouth secrete smaller amounts of saliva. Technavio’s analysts forecast the Global Sjogren’s Syndrome...
110 pages •
By Infiniti Research Limited
• Oct 2018
About Diffuse Large B-Cell Lymphoma DLBCL is a cancer of B-lymphocytes. It is the most common type of NHL among adults. It is an aggressive (fast-growing), complex, and difficult-to-treat form of NHL, which refers to a group of cancers of the lymphatic system. Technavio’s analysts forecast the Global DLBCL Therapeutics...